CODXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Co-Diagnostics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.67+0.01 (+1.83%)

Close on Oct 19, 2026

Market cap: $2.87M
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Co-Diagnostics reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Co-Diagnostics's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Co-Diagnostics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-30 reverse split on Mar 31, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CODX.

Revenue growth-28.1% · median 21.9%

Gross margin43.5% · median 56.9%

Operating margin-6787.6% · median -763.9%

Net margin-6523.0% · median -827.3%

Company	Revenue	Growth
LUCD	$5.45M	+24.9%
INBS	$4.22M	+38.1%
FEMY	$2.30M	+21.9%
SINT	$1.33M	-28.5%
PETV	$1.18M	-9.5%
CODX	$721.39K	-28.1%

Company

Next earnings (est.): Nov 12, 2026, after close
Exchange: Nasdaq
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: December 31
Employees: 115
Held by institutions: 9.5%
Auditor: Tanner LLP
SEC CIK: 1692415

Advertisement
300 × 250